You have full text access to this Open Access content

EMBO Molecular Medicine

All articles accepted from 14 August 2012 are published under the terms of the Creative Commons Attribution License.   Articles accepted before this date were published under the agreement as stated in the final article.

Cover image for Vol. 7 Issue 5

Edited By: Stefanie Dimmeler (Chief Editor), Roberto Buccione and Céline Carret (EMBO Editors)

Online ISSN: 1757-4684

Board Member Biographies

We are pleased to introduce the new members of the EMBO Molecular Medicine Advisory Board. Members of the Board provide scientific advice to the editors for which we are very grateful. A full list of the Advisory Board is also available.

Should you wish to contact a Board member about EMBO Molecular Medicine, please do so through the Editorial Office: info@embomolmed.org


EMBO Molecular Medicine - Martin Gleave

Martin Gleave

The Prostate Centre at VGH Urologic sciences Vancouver, British Colombia, Canada
Prof. Martin Gleave is a Distinguished Professor and Vice Chair of the Department of Urologic Sciences at the University of British Columbia (UBC) Canada, Director of the Vancouver Prostate Center, and a British Columbia Leadership Chair. Prof. Gleave¹s research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on stress-activated adaptive responses that drive acquired treatment resistance, and designing rational combination co-targeting strategies to create conditional lethality and improve cancer control. He founded OncoGenex Pharmaceuticals to develop inhibitors targeting cytoprotective chaperones clusterin (OGX-011) and Hsp27 (OGX-427) now in Phase II and III trials in several cancers.

EMBO Molecular Medicine - Oliver Eickelberg

Oliver Eickelberg

Institute of Lung Biology and Disease, Ludwig-Maximilians-University, Munich, Germany
Professor Oliver Eickelberg is Chairman of the Comprehensive Pneumology Center/Institute of Lung Biology and Disease, Ludwig-Maximilians-University and Helmholtz Zentrum München and Vice Chairman, German Center for Lung Research (DZL). Professor Eickelberg studies the mechanisms of structural remodelling of the lung in chronic lung diseases, such as Idiopathic Pulmonary Fibrosis (IPF) or Chronic Obstructive Pulmonary Disease (COPD). His research focuses on characterising and regenerating functional lung tissue in disease, by focusing on fibrotic signalling pathways (e.g. TGF-beta), epithelial-mesenchymal interaction, and dynamics of extracellular matrix composition. His work aims at translating these findings to clinical practice by uncovering new biomarkers and therapeutic regimens.

EMBO Molecular Medicine - Robert Kerbel

Robert Kerbel

Department of Medical Biophysics, University of Toronto, Canada
Prof. Robert Kerbel is Canada Research Chair in Tumor Biology, Angiogenesis, and Antiangiogenic Therapy and a professor in the Dept. of Medical Biophysics at the University of Toronto. His main interest has been to devise new cancer treatment strategies having both improved efficacy and reduced toxicity. A number of his findings are now being evaluated in clinical trials, particularly in breast, ovarian, colorectal, and various pediatric cancers. His contributions include the development of improved preclinical models involving early stage or advanced metastatic disease for experimental therapeutic investigations and elucidating mechanisms of acquired antiangiogenic drug resistance.

EMBO Molecular Medicine - Guido Kroemer

Guido Kroemer

INSERM, U848, Villejuif, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Prof. Guido Kroemer is best known for the discoveries that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death, that autophagy is a cytoprotective mechanisms that ­ if induced at the whole-body level ­ increases lifespan, and that antineoplastic therapies are only successful if they stimulate anticancer immune responses. He received the Descartes Prize of the European Union, the Carus Medal of the Leopolidina, the Dautrebande Prize of the Belgian Royal Academy of Medicine, the Léopold Griffuel Prize of the French Association for Cancer Reseach, as well as a European Research Council Advanced Investigator Award. He is the director of the Paris Alliance of Cancer Research Institutes and of the Labex Immuno-Oncology.

EMBO Molecular Medicine - Bernd Nilius

Bernd Nilius

Department Cell Mol Medicine, KU Leuven, Belgium
Bernd Nilius is Emeritus Professor at KU Leuven (Belgium), where he worked until 2010 as Full Professor of Physiology and from 2005-2010 as Director of the "Center of Excellence: TRP Channels". He discovered cardiac T-type Ca2+ channels, volume-regulated anion channels in vascular endothelium and has initiated a very successful research on TRP cation channels. His work has strong connections to the role of ion channels in hereditary and aquired diseases (channelopathies), which led e.g. to the discovery of the role of TRPV4 channels in skeletal dysplasias and neuropathies. He is member of several Academies, of EMBO and has received some prestiguos prizes such as the Dautrebade award presented by the Queen of Belgium.

EMBO Molecular Medicine - Kornelia Polyak

Kornelia Polyak

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Prof. Kornelia Polyak is Professor of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA. Prof. Polyak's laboratory is dedicated to the molecular analysis of human breast cancer. The goal is to better understand the molecular evolution of human breast tumors and to use this information to improve the clinical management of breast cancer patients. The areas of major focus of the her laboratory are currently: better understanding the clinical and biological relevance of tumor heterogeneity, the role of microenvironment in tumor progression and therapeutic responses, molecular and cellular mechanisms of breast cancer risk, the role of epigenetic mechanism in breast cancer subtypes and heterogeneity, and new therapeutic targets in breast cancer.

SEARCH

SEARCH BY CITATION